Novartis completes Avidity Biosciences acquisition
The deal closed on February 27, 2026. Novartis thanks its team and partners for their support during this significant corporate milestone.
See the latest news and media coverage for Avidity Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing targeted RNA therapeutics
aviditybiosciences.comLast updated
In short: Avidity Biosciences was acquired by Novartis in a completed $12 billion deal
The deal closed on February 27, 2026. Novartis thanks its team and partners for their support during this significant corporate milestone.
The company highlights patient resilience and its commitment to developing impactful therapies during Rare Disease Day.
The companies join forces to expand RNA therapeutic possibilities for patients.
Novartis gains the neuroscience pipeline and RNA platform, while Avidity’s cardiology division spins off into a new public entity.
Del-desiran, Avidity BioSciences' main drug, fails in clinical trial causing million-dollar losses.
Avidity Biosciences stock left Nasdaq after Novartis completed its USD 12 billion acquisition on February 27, 2026. The deal offered USD 72.00 per share.
Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA...
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision...
Track Avidity Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Avidity Biosciences and other trending companies.